SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Resverlogix Corporation Announces Full Enrollment of SUSTAIN, a Phase 2b Clinical Trial Targeting High-Risk Cardiovascular Disease Patients